There is some confusion in the discussion about exactly what the Fleischner Society 2017 guideline (FG) and BTS guideline say about part solid nodules that I feel unfairly criticises the BTS. The FG does mention management by size of solid component in the text, but does not specifically state to manage according to this a recommendation . The BTS similarly in both the text and the evidence statements ( which FG does not have at all) that size of solid component, development of solid component, enlargement of solid component are all predictors of malignancy and makes specific and clear recommendations concerning appearance and growth of the solid component, not present in the FG.
INTRODUCTION
"Pulmonary subsolid nodules (SSNs) represent a histologic spectrum of adenocarcinoma and its preinvasive precursors, including atypical adenomatous hyperplasia (AAH), adenocarcinoma-in-situ (AIS), minimally invasive adenocarcinoma (MIA) and invasive pulmonary adenocarcinoma (IPA) ." This wording leaves the impression that minimally invasive adenocarcinoma (MIA) and invasive pulmonary adenocarcinoma (IPA) are preinvasive precursors, which is not correct.
That the Brock and Lee models have similar AUCs (0.75 and 0.77, p=0.62 ) is encouraging for the Brock model, which was developed on all nodules, not focusing on GGO and semisolid nodules alone. The Lee model was developed specifically on ground glass and semisolid nodules, so one would have expected it to perform better when tested on GGO and semisolid nodules alone.
" Lee et al.7 also developed a prediction model (Lee model) using simple size metrics and morphologic features for the differentiation of invasive adenocarcinomas appearing as SSNs." Lee and colleagues also included pure ground glass nodules in their model development.
The current study population consists of clinical cases surgically resected for lung cancer. The Brock model was developed for use in a general screening population at high risk for lung cancer, none of which were hospitalized or under active clinical investigation for lung cancer. These are very different populations.
Page 6. "Therefore, a total of 430 nodules from 410 patients were analyzed in the present study (figure 1)." It seems that only resected nodules were evaluated. How were pGG and SSN nodules showing up on the CT scan that were not resected followed up to determine if they represented cancer or not? Were they excluded from analysis. Their cancer or invasive status would need to be determined by follow-up but none is described.
When more than one nodule occurred in one person, how was clustering handled in analysis?
Statistical Analysis "we first performed univariate analysis. Categorical variables were analyzed using the Pearson Chi-square test or Fisher's exact test and continuous variables were analyzed using the independent t-test or Mann-Whitney U test, as appropriate." Clustering of nodules within individuals occurred. How was this nonindependence of observations handled statistically? "Therefore, predicted probability was obtained only for PSNs in terms of the Lee model." No probability for pure GGO nodules was not estimated by the Lee model. The comparison of AUCs was based only on PSNs. This is a study limitation. What was the AUC for the Brock model when GGO nodules were included with PSN, not separated from them?
In Table 2 the tests for statistically significant difference between AAH and AIS versus MIA and IPA appear to lack power and also do not take into account clustering of data within individuals who have multiple nodules. From Table 2 , the crude odds ratio for spiculation and MIA/IPA is 5.5. Clearly, this appears to be a strong effect, and yet it only had a p-value of 0.14 and was considered non-significant. The study lacks power. No a priori sample size calculations were prepared. Table 2 footnotes describes the cell number to refer to individuals. When multiple nodules occurred in a person, then which nodule was counted in the table, for example in location, spiculation, and nodule size. Table 4 . Accuracy is a poor measure in most clinical settings, especially if the prevalence of disease is not reported next to it to facilitate interpretation. Table 4 and text. For the Lee model an AUC could be calculated for pure GG nodules by assigning everyone with 10 mm or more a probability of 1.0 and those <10 mm a probability of 0, as this is in effect what the Lee model does. Doing this would allow analysis of pGG and semisolid nodules pooled together, which makes statistical and clinical sense and would allow comparison of Brock and Lee models side by side in a larger sample. Also, each time the sampling strata is made smaller and more homogeneous, the lower the AUC will be, underestimating the expected AUC in a real-world setting.
For Tables 4 and 5 the number of cases and non-cases should be stated.
Discussion
Page 16. "McWilliams et al.16 originally developed a lung cancer prediction model (Brock model) using participants enrolled in a lung cancer screening study and chemoprevention trials." The Brock model was developed using the screening trial participant data only. Validation was in the chemoprevention trial participant data.
Page 17." Past research on distinguishing invasive adenocarcinomas appearing as SSNs have reported that logistic regression models built with size metrics, morphologic features, or texture features showed AUCs ranging from 0.79 to 0.98.4-7 9 11 13 However, these models were not tested for an independent cohort or validated externally. Therefore, their true performance may be lower than that reported in the literature." Their true performance will almost certainly be lower than reported. External validation most often leads to a drop in prediction, but some of the models referenced were based on neural networking, which is notorious for overfitting models to idiosyncratic patterns in data and often have low reproducibility.
The AUCs observed in the current study may be underestimate for the what may be expected in a screening or non-surgical setting. But even given the limiations of the current study, the AUCs are not bad. According to Hosmer and colleagues (Hosmer DW, Lemeshow S, Sturdivant RX. Applied logistic regression, Third Edition. Hoboken, New Jersey: Wiley; 2013.) An AUC of .7 to <.8 is acceptable discrimination and .8 to <.9 is excellent discrimination.
Page 17. "Another important finding of our study was that the PPV for the differentiation of invasive lesions among PSNs was very high for both models, over 95%. In other words, the probability of being an invasive lesion was over 95% for nodules predicted as being invasive through these models."
The PPV is very strongly driven by the proportion of disease in the sample under study. The prevalence of invasive cancer in the screening setting or incident nodule setting is relatively uncommon compared to this study's setting. The reported PPVs does not estimate what is expected in practice.
Page 17. "The diagnostic accuracies of both the Brock model and Lee criteria were even lower for pGGNs. Among multiple clinical and radiologic characteristics investigated in our study, only three variables (family history of lung cancer, nodule size, and nodule count per scan) were significantly different between preinvasive and invasive lesions." Diagnostic accuracy depends on sensitivity, specificity and the proportion of cases to controls. Just like the PPV, the accuracy reported does not reflect what will be observed in the clinical setting of screen detected nodules or incidental nodules. That few relationships were statistically significant in this study does not reflect that relationships do not exist, but rather that the study is underpowered. An example was provided earlier about spiculation.
Page 19. "Second, optimal cutoffs for the models were not obtained from ROC analyses of the original study populations from which the models were derived. Therefore, performance metrics including sensitivity, specificity, accuracy, PPV and NPV may have been overestimated in our study." As one selects a narrower and narrower group to study, everyone in the sample becomes more alike and it becomes harder to discriminate cases from controls. In the current study, the sample was homogeneous and the authors even separated pure ground glass nodules from semisolid ground glass nodules for analysis. Given this sampling and analytic approach, it is expected that the AUC were underestimated compared to what is expected in the realworld setting.
Page 19. "However, recent analyses have revealed that the usage of average diameter as an input variable may enhance the model performance.28 29 Reference 28 is the Kovalchik paper which models prediction of lung cancer mortality not nodule malignancy probability. I believe that there is no appropriate reference to mean nodule size in that paper. No discussion of fit of findings with Lung-RADS nodule management recommendations.
REVIEWER
Lori Sakoda, PhD Kaiser Permanente Northern California, USA REVIEW RETURNED 25-Nov-2017
GENERAL COMMENTS
Kim and colleagues examined the performance of two prediction models in differentiating minimally-invasive and invasive pulmonary adenocarcinoma (MIA/IPA) from preinvasive lesions among patients with incidentally-detected subsolid nodules (SSNs) at a single hospital in Korea. Their work addresses the need for greater external validation of existing risk prediction models for pulmonary nodule malignancy. Although both models were not found to discriminate as well as previously reported, calibration should be analyzed and presented, along with discriminatory accuracy, when assessing model performance. This manuscript would also be strengthened by inclusion of some additional methodological details and interpretation of study results, as specified below.
Clarify rationale for selecting Brock and Lee models for validation. To date, many prediction models have been developed to estimate nodule malignancy risk, of which very few have been compared head-to-head in independent external validation studies. It is not entirely clear why the Brock and Lee models were specifically selected and why other existing models were not also examined.
Clarify description for nodule count per scan. The methods (page 6) indicate that 19 of the 410 patients had more than one nodule. In Table 1 , however, the median number of nodules per scan is 3, which seems high and inconsistent with the majority of patients having solitary pulmonary nodules.
Offer greater insight into factors that may have influenced predictive performance. The discussion could be expanded to discuss why both models may not have performed as well. In particular, the extent to which the study population examined is similar to the populations in which each model was initially developed is not described. McWilliams and colleagues developed the Brock model using data from trial participants with screening-detected nodules, among which the prevalence of malignancy was relatively low (<6%). Those participants also constituted a high-risk population, defined by age and smoking history. In this study, participants had incidentally detected SSNs, among which the prevalence of malignancy was 83.5%, with no information presented on smoking history. Presumably, the study population was more similar to that in which the Lee model was developed, although surprisingly, performance was fairly comparable between the two models.
Note sample size as a study limitation. The study population included 410 patients with 430 SSNs; however, analyses were conducted separately for pure ground-glass nodules (n=106) and part-solid nodules (n=324).
Provide more detailed description of study participants in abstract. For clarity, please specify that patients had incidentally detected SSNs and underwent surgical resection from 2011 to 2015.
Provide supplemental information about Lee model. To support future replication, please provide the equation from logistic regression model used to estimate the probability of PSN malignancy, as predicted by nodule size, solid proportion, lobulation, and spiculation. This information was not published in the original paper by Lee et al.
REVIEWER
Colin Jacobs Radboudumc, Nijmegen, the Netherlands REVIEW RETURNED 08-Dec-2017
GENERAL COMMENTS
This paper investigates the use of two prediction models to differentiate minimally invasive and invasive pulmonary adenocarcinoma's from preinvasive adenocarcinomas. To do this, the authors collected all surgically resected SSNs between 2011 and 2015 from their hospital, scored the necessary CT parameters of the models and evaluated the performane of these models. One of the models, the Brock model, is now incorporated in important clinical guidelines (BTS and Lung-RADS) so this is an important evaluation study.
(1) the brock model is not designed to make the differentation between invasive and preinvasive lesions -it just estimates the probability of malignancy, where invasive and in situ adenocarcinoma's are treated the same. Table 1 in the publication by McWilliams et al. shows that there were also AIS cancers in the development data set of the Brock model and they are treated the same as invasive adenocarcinoma when the model was made. But I do see the argument of the authors of this paper that the Brock model is now being used in the BTS guidelines as a risk stratifier for subsolid nodules while this model does not look at invasiveness of the tumor at all. Hence, I think it is valuable that this paper shows that the Brock model is not good at distinguishing preinvasive from invasive SSNs. If the authors make this more clear in the paper, I think this would strengthen the paper.
(2) the selection of nodules: these are all suspicious SSNs, and the vast majority are invasive adenocarcinoma's (83.5%). However, there is no other way to have a good reference standard whether a SSN is invasive or preinvasive than resecting it, so I am also willing to accept this limitation. It is already clearly mentioned by the authors in the discussion.
VERSION 1 -AUTHOR RESPONSE
Point-by-point response letter to the reviewers' comments Editor Comments to Author: 1. Along with your revised manuscript, please include a copy of the TRIPOD checklist indicating the page/line numbers of your manuscript where the relevant information can be found (http://www.equator-network.org/reporting-guidelines/tripod-statement/) → Thank you. We included a copy of the TRIPOD checklist as you recommended.
2. Please revise the title of your manuscript to include the research question, study design and setting. This is the preferred format of the journal. → We followed your comment and revised the title of our manuscript.
Reviewer: 1 Reviewer Name: David R Baldwin Institution and Country: Nottingham University Hospitals, UK Please state any competing interests or state 'None declared': None Please leave your comments for the authors below This is a well-written and very relevant paper on SSNs. I have only two comments that I feel require addressing to make this paper complete.
1. The authors do not say why the Lee model is not used to predict malignancy in pGGN (or at least I have missed it). Please make the reason clear and include in the abstract. → Thank you for your comment and review. In our study, both Brock model and Lee model were used to predict malignancy (invasive lesions) in pGGNs and in PSNs. However, for the Lee model, ROC analysis was not performed for pGGNs as there was a single cutoff (nodule size, 10 mm). Malignancy probability of each pGGNs could not be obtained. Thus, AUC was not calculated for pGGNs. Other performance measures of diagnostic accuracy, sensitivity, specificity, PPV and NPV were described in the manuscript. ROC analysis was conducted for only PSNs for the Lee model. → First of all, we understand that the BTS guideline was established based on the best available evidences. We also believe that the BTS guideline is very useful for the clinicians as well as for the radiologists in practice. In addition, our aim was to evaluate the performance of the existing prediction models and was not to compare the guidelines from different organizations. We further discussed the management guidelines for PSNs in the Discussion section as you suggested. We described the recommendations from the Fleischner Society and BTS as follows. "A few studies have shown that the solid portions in PSNs are well correlated to the pathologic invasive component.12 27 28 Fleischner Society guideline recommends that PSNs with solid components ≥6 mm be monitored with CT scans at 3-6 months interval.26 PSNs with solid portions larger than 8 mm should be biopsied or surgically resected in consideration of invasive adenocarcinomas.26 BTS also recommends that the solid component size be considered to further refine the estimate of malignancy risk.21 In addition, growing solid component is also a sign of an invasive adenocarcinoma as described in both guidelines.21 26"
Reviewer: 2 Reviewer Name: Martin Tammemagi Institution and Country: Brock University, Canada Please state any competing interests or state 'None declared': I am the developer of the Brock nodule malignancy probability model, which was one of the two models being evaluated in the current paper.
Please leave your comments for the authors below Note to editor: In the review checklist provided with 15 points, often the answer was not a clear yes or no, and needed clarification. The checklist does not accurately summarize the thinking in this review. Comments for authors and editors: Primary Issues:
• Study sample is not representative and generalizability is questionable.
• The study sample size is underpowered.
• Some analytic approaches may need correction (adjusting for clustering) and other statistical approaches may need improvement (1. pooling of pGG and SSN and analyzing together, 2. In tables clarifying nodule-based versus individual-based results).
The following comments are presented in chronological order as the occurred reading trough the manuscript. They do not reflect the relative importance of comments. Abstract 1. "410 patients with 430 SSNs who underwent surgical resection for the pulmonary adenocarcinoma spectrum." This is a narrow unrepresentative sample. They all underwent surgical resection. These individuals are from a surgical hospital-based sample. This sample does not represent screen detected or incidental SSN and thus evaluation of prediction in this sample is questionable. The proportion of non-invasive SSN is very low.
→ Thank you for your intensive review and comments on our paper. We appreciate your valuable critique. We understand your concern that the narrow spectrum of our study population may limit the generalizability of the study results. Nevertheless, most of the persistent SSNs fall into one of the four disease categories of AAH, AIS, MIA and IPA. Therefore, a clinical decision, whether to resect/biopsy a SSN or to follow-up with CT scans, has to be made in routine practice. This is a very common situation.
Our intent was to demonstrate the performance of the existing prediction models in discriminating invasive lesions and thus to evaluate the usefulness of those models in the clinical decision making. Pathologic gold standard was required to demonstrate the invasiveness of nodules. The natural course of SSNs differ substantially from that of the solid lung cancers. SSNs usually grow very slowly. According to a study by Chang et al. (reference #1) , the volume doubling time of pGGNs ranged from 330 to 3031 days. Actually, only 9.8% of the pGGNs grew in that study (median follow-up, 59 months), and majority of the nodules did not show any growth during the long term follow-ups. Nevertheless, it is not possible to diagnose those non-growing nodules as preinvasive invasions, and to determine the invasiveness or the malignancy probability of these nodules based on the follow-up CT scans. Therefore, we believed that the investigations for the surgically resected nodules were essential for SSNs to establish the gold standard. We hope you can understand our predicament. All SSNs included in the present study were incidentally detected. SSNs are indolent lesions and do not provoke any symptoms. Thus, CT scans, hospitalization, or other active investigations were not performed in order to find SSNs in these patients. All SSNs were found incidentally. Lastly, we admit that the proportion of preinvasive lesions was low as these lesions, which are usually small pGGNs, do not require surgical resections. Nevertheless, as you can understand, we cannot include the non-pathologically confirmed cases (particularly pGGNs) in our study and designate them as preinvasive lesions. Actually no body knows exactly what they are without pathological confirmation! In the cases of SSNs, small tissue sampling through needle biopsy cannot give an answer for their definitive diagnosis because we should examine the whole pathological parts within the entire lesion. However we understand your point and we also feel that a prospective validation of the prediction models with long term follow-up is definitely required for the consecutive patients with incidentally detected SSNs. 2. "Participants: 410 patients with 430 SSNs who underwent surgical resection for the pulmonary adenocarcinoma spectrum". We don't know the proportion of lung cancers in the sample. It is impossible to interpret values, especially PPVs and NPVs without knowing the proportion of the sample with disease. The proportion of invasive lung cancers needs to be described early in the paper, and together with statistics which depend on the prevalence of disease, such as accuracy and PPV, in text and tables. → We followed your comment. We stated the numbers of preinvasive and invasive lesions in the abstract as well as in the tables.
3. The Conclusion in the Abstract is overstated. Prediction in a homogeneous risk population, as in the current study SSN, is much more difficult to achieve than in a heterogeneous sample. Given the restricted homogeneous sample, it is not surprising that the prediction is not high. "For part-solid nodules, the AUC was 0.748 for the Brock model and 0.769 for the Lee model (P=0.623)." This sentence describes good prediction for a homogeneous subset of lung cancers. → Thank you very much for your thorough review. We changed the conclusion of the Abstract as follows.
"The performance of prediction models for the incidentally detected SSNs in differentiating MIA/IPA from preinvasive lesions might be suboptimal. Thus, an alternative risk calculation model is required for the incidentally detected SSNs." We also agree with your comment. The performance might be underestimated in our population as we analyzed pGGNs and PSNs separately. However, from the clinical perspective, incidentally or screening detected nodules are managed according to their nodule type (solid, pure ground-glass, or part-solid) and size. Guidelines from the Fleischner Society, British Thoracic Society, and American College of Chest Physicians suggest the same approach. Thus, we assumed that the separation of nodule groups according to their morphologic types conformed to the current clinical practice. We described this issue as one of the limitations in the Discussion section. In addition, we performed a pooled ROC analysis for the entire SSNs as you suggested below. AUC of the Brock model was 0.810 for the entire SSNs.
4. "The main limitation of this study is that it only analyzed surgically resected lung nodules, thus inducing selection bias." This is a major limitation. The findings no longer apply in the setting in which they might be useful, which includes screen detected or incidental findings. → Please refer to our reply to #1. In addition, we clearly stated this issue as a limitation of our study as follows. "First, our study was not conducted for a screening cohort as described earlier in this manuscript. The prevalence of preinvasive lesions was low compared to that of the screening setting. Thus, the performance measures in this study should be carefully interpreted with respect to the target population, which were the incidentally detected surgical candidates."
INTRODUCTION 5. "Pulmonary subsolid nodules (SSNs) represent a histologic spectrum of adenocarcinoma and its preinvasive precursors, including atypical adenomatous hyperplasia (AAH), adenocarcinoma-in-situ (AIS), minimally invasive adenocarcinoma (MIA) and invasive pulmonary adenocarcinoma (IPA)."
This wording leaves the impression that minimally invasive adenocarcinoma (MIA) and invasive pulmonary adenocarcinoma (IPA) are preinvasive precursors, which is not correct. → We agree with your comment. We revised the sentence as follow. "a histologic spectrum of adenocarcinoma and its preinvasive precursors, including atypical adenomatous hyperplasia (AAH) and adenocarcinoma-in-situ (AIS)" 6. That the Brock and Lee models have similar AUCs (0.75 and 0.77, p=0.62) is encouraging for the Brock model, which was developed on all nodules, not focusing on GGO and semisolid nodules alone. The Lee model was developed specifically on ground glass and semisolid nodules, so one would have expected it to perform better when tested on GGO and semisolid nodules alone. → We agree with your comment.
7. "Lee et al.7 also developed a prediction model (Lee model) using simple size metrics and morphologic features for the differentiation of invasive adenocarcinomas appearing as SSNs." Lee and colleagues also included pure ground glass nodules in their model development. → Subsolid nodule (SSN) is a term including both pure ground-glass nodule (pGGN) and part-solid nodule (PSN).
8. The current study population consists of clinical cases surgically resected for lung cancer. The Brock model was developed for use in a general screening population at high risk for lung cancer, none of which were hospitalized or under active clinical investigation for lung cancer. These are very different populations. → We understand your concern. Our intent was not to criticize the performance of the Brock model for the screening-detected nodules. The model performance was already proven to be excellent through several external validation studies as stated in the manuscript.
The current British Thoracic Society (BTS) guideline recommends that the initial evaluation of a persistent SSN ≥ 5mm, regardless of the mode of detection, be based on the risk prediction model, specifically the Brock model. Therefore, the purpose of our study was to apply clinical cases, whether the patients were hospitalized or under active investigation, to the Brock model. This issue is directly related to the clinical practice and guideline conformity. Therefore, we believe that our study gains clinical implication.
9. Page 6. "Therefore, a total of 430 nodules from 410 patients were analyzed in the present study (figure 1)." It seems that only resected nodules were evaluated. How were pGG and SSN nodules showing up on the CT scan that were not resected followed up to determine if they represented cancer or not? Were they excluded from analysis. Their cancer or invasive status would need to be determined by followup but none is described. → SSNs show a kind of unique clinical behavior, which can be quite different from solid lung nodules. In the cases of solid pulmonary nodules, we have made decision whether they are benign or malignant based on the evolution over follow-up studies. However, interestingly, stable clinical course of SSNs cannot guarantee their benignity and stable SSNs can be malignant pathologically. Growing lesions are more likely to be invasive lesions. However, not all invasive lesions grow over follow-ups. Thus, the true nature of SSNs can only be diagnosed through the histopathologic examination at this point in time.
In this context, only surgically-resected and pathologically-confirmed SSNs were included. Lesions that underwent CT surveillance and were not pathologically-confirmed were excluded from the analysis. We hope you can understand our predicament.
10. When more than one nodule occurred in one person, how was clustering handled in analysis? → We repeated the overall analysis to exclude the with-subject correlation as you commented. A single nodule was selected randomly for the patients with multiple nodules. Therefore, all study results were revised throughout the manuscript. However, there were no changes in the results of the statistical testing.
Statistical Analysis 11. "we first performed univariate analysis. Categorical variables were analyzed using the Pearson Chi-square test or Fisher's exact test and continuous variables were analyzed using the independent t-test or Mann-Whitney U test, as appropriate." Clustering of nodules within individuals occurred. How was this non-independence of observations handled statistically? → We repeated the overall analysis to exclude the with-subject correlation as you commented. A single nodule was selected randomly for the patients with multiple nodules. Therefore, all study results were revised throughout the manuscript. However, there were no changes in the results of the statistical testing.
12. "Therefore, predicted probability was obtained only for PSNs in terms of the Lee model." No probability for pure GGO nodules was not estimated by the Lee model. The comparison of AUCs was based only on PSNs. This is a study limitation. What was the AUC for the Brock model when GGO nodules were included with PSN, not separated from them? → We performed ROC analysis for the entire SSNs for the Brock model as you suggested. AUC of the Brock model was 0.810 (95% CI: 0.769, 0.846). We described the results in the manuscript.
13. In Table 2 the tests for statistically significant difference between AAH and AIS versus MIA and IPA appear to lack power and also do not take into account clustering of data within individuals who have multiple nodules.
From Table 2 , the crude odds ratio for spiculation and MIA/IPA is 5.5. Clearly, this appears to be a strong effect, and yet it only had a p-value of 0.14 and was considered non-significant. The study lacks power. No a priori sample size calculations were prepared. → We admit that the small study population is a limitation of our study as you stated. We stated this issue in the second to last paragraph of the Discussion section.
14. Table 2 footnotes describes the cell number to refer to individuals. When multiple nodules occurred in a person, then which nodule was counted in the table, for example in location, spiculation, and nodule size. → We repeated the overall analysis after random selection of a single nodule for the patients with multiple nodules. Thus, a single nodule per patient was analyzed for all study population.
15. Table 4 . Accuracy is a poor measure in most clinical settings, especially if the prevalence of disease is not reported next to it to facilitate interpretation. → We added the prevalence of disease (numbers of preinvasive and invasive lesions, respectively) in the abstract, main body and tables.
16. Table 4 and text. For the Lee model an AUC could be calculated for pure GG nodules by assigning everyone with 10 mm or more a probability of 1.0 and those <10 mm a probability of 0, as this is in effect what the Lee model does. Doing this would allow analysis of pGG and semisolid nodules pooled together, which makes statistical and clinical sense and would allow comparison of Brock and Lee models side by side in a larger sample. Also, each time the sampling strata is made smaller and more homogeneous, the lower the AUC will be, underestimating the expected AUC in a real-world setting. → Thank you for your suggestion. We followed your comment and performed a ROC analysis for the entire SSNs for the Brock model. AUC for the entire SSNs was 0.810 and this showed that the separate analysis of pGGNs and PSNs for the Brock model might have resulted in the slight underestimation of the model performance as you stated. We described as such in the limitation paragraph of the Discussion section. However, for the Lee model, pooled analysis was not conducted. Assigning nodules ≥10 mm a probability of '1.0' and assigning nodules <10 mm a probability of '0' would be an appropriate statistical option. Nevertheless, this cutoff of 10 mm was selected in order to optimize the sensitivity for the detection of invasive adenocarcinomas. That is, there were no invasive adenocarcinomas smaller than 10 mm in the original paper of the Lee model. Given that this cutoff was chosen based on a clinical judgement to optimize the sensitivity and that the original study by Lee et al. displayed separate analyses according to the nodule type, pooling of the two heterogeneous nodule probability groups was not deemed an appropriate methodology. Therefore, ROC analysis for the entire SSNs was conducted only for the Brock model. Tables 4 and 5 the number of cases and non-cases should be stated. → We followed your suggestion and added the numbers of cases and non-cases in the footnotes. 19. Page 17." Past research on distinguishing invasive adenocarcinomas appearing as SSNs have reported that logistic regression models built with size metrics, morphologic features, or texture features showed AUCs ranging from 0.79 to 0.98.4-7 9 11 13 However, these models were not tested for an independent cohort or validated externally. Therefore, their true performance may be lower than that reported in the literature." Their true performance will almost certainly be lower than reported. External validation most often leads to a drop in prediction, but some of the models referenced were based on neural networking, which is notorious for overfitting models to idiosyncratic patterns in data and often have low reproducibility. → We agree with your opinion.
For
20. The AUCs observed in the current study may be underestimate for the what may be expected in a screening or non-surgical setting. But even given the limitations of the current study, the AUCs are not bad.
According to Hosmer and colleagues (Hosmer DW, Lemeshow S, Sturdivant RX. Applied logistic regression, Third Edition. Hoboken, New Jersey: Wiley; 2013.) An AUC of .7 to <.8 is acceptable discrimination and .8 to <.9 is excellent discrimination. → Thank you for the valuable comment. We also consider that the AUCs of 0.7-0.8 demonstrated in our study is not bad and have diagnostic value. However, 'acceptable' is quite arbitrary and confusing to the readers. Thus, we would like to display the values themselves in the manuscript without judgement of being 'bad, acceptable or excellent'.
21. Page 17. "Another important finding of our study was that the PPV for the differentiation of invasive lesions among PSNs was very high for both models, over 95%. In other words, the probability of being an invasive lesion was over 95% for nodules predicted as being invasive through these models."
The PPV is very strongly driven by the proportion of disease in the sample under study. The prevalence of invasive cancer in the screening setting or incident nodule setting is relatively uncommon compared to this study's setting. The reported PPVs does not estimate what is expected in practice. → We agree with your comment that the prevalence of preinvasive lesions was low in our study population. We clearly stated this issue as a limitation of our study as follows. "First, our study was not conducted for a screening cohort as described earlier in this manuscript. The prevalence of preinvasive lesions was low compared to that of the screening setting. Thus, the performance measures in this study should be carefully interpreted with respect to the target population, which were the incidentally detected surgical candidates."
22. Page 17. "The diagnostic accuracies of both the Brock model and Lee criteria were even lower for pGGNs. Among multiple clinical and radiologic characteristics investigated in our study, only three variables (family history of lung cancer, nodule size, and nodule count per scan) were significantly different between preinvasive and invasive lesions." Diagnostic accuracy depends on sensitivity, specificity and the proportion of cases to controls. Just like the PPV, the accuracy reported does not reflect what will be observed in the clinical setting of screen detected nodules or incidental nodules. That few relationships were statistically significant in this study does not reflect that relationships do not exist, but rather that the study is underpowered. An example was provided earlier about spiculation. → We admit that the sample size might not be large enough to demonstrate the statistical significance. We stated this issue in the second to last paragraph of the Discussion section.
23. Page 19. "Second, optimal cutoffs for the models were not obtained from ROC analyses of the original study populations from which the models were derived. Therefore, performance metrics including sensitivity, specificity, accuracy, PPV and NPV may have been overestimated in our study." As one selects a narrower and narrower group to study, everyone in the sample becomes more alike and it becomes harder to discriminate cases from controls. In the current study, the sample was homogeneous and the authors even separated pure ground glass nodules from semisolid ground glass nodules for analysis. Given this sampling and analytic approach, it is expected that the AUC were underestimated compared to what is expected in the real-world setting. → We understand your concern and we stated this issue as follows in the second to last paragraph of Please leave your comments for the authors below 1. Kim and colleagues examined the performance of two prediction models in differentiating minimally-invasive and invasive pulmonary adenocarcinoma (MIA/IPA) from preinvasive lesions among patients with incidentally-detected subsolid nodules (SSNs) at a single hospital in Korea. Their work addresses the need for greater external validation of existing risk prediction models for pulmonary nodule malignancy. Although both models were not found to discriminate as well as previously reported, calibration should be analyzed and presented, along with discriminatory accuracy, when assessing model performance. This manuscript would also be strengthened by inclusion of some additional methodological details and interpretation of study results, as specified below. → We followed your suggestion. Along with the discrimination analysis, model calibration was assessed using Hosmer-Lemeshow goodness of fit test for the 10 probability groups (deciles). Models tested showed poor calibration. We described the method and the results as such in the manuscript.
2. Clarify rationale for selecting Brock and Lee models for validation. To date, many prediction models have been developed to estimate nodule malignancy risk, of which very few have been compared head-to-head in independent external validation studies. It is not entirely clear why the Brock and Lee models were specifically selected and why other existing models were not also examined.
→ First, Brock model was selected as this was incorporated in the recent BTS guideline for the management of SSNs. Brock model was built based on the analysis of solid, pure ground-glass and part-solid nodules. To our knowledge, Brock model is the only quantitative risk prediction model which is applicable to SSNs and at the same time incorporated in the management guidelines published by the authoritative organizations. Second, Lee model was selected as this model was constructed based on the similar inclusion criteria compared to the present study and focused specifically on the SSNs.
3. Clarify description for nodule count per scan. The methods (page 6) indicate that 19 of the 410 patients had more than one nodule. In Table 1 , however, the median number of nodules per scan is 3, which seems high and inconsistent with the majority of patients having solitary pulmonary nodules. → A lot of patients in our study population had multiple nodules, which were not surgically resected. Among those nodules only surgically resected nodules with pathologic diagnoses were included in the analysis. Therefore, most of the patients (410/430) had only a single resected nodule.
We repeated the overall analysis after selection of a single nodule randomly for the patients with multiple nodules to exclude within-subject correlation.
4. Offer greater insight into factors that may have influenced predictive performance. The discussion could be expanded to discuss why both models may not have performed as well. In particular, the extent to which the study population examined is similar to the populations in which each model was initially developed is not described. McWilliams and colleagues developed the Brock model using data from trial participants with screening-detected nodules, among which the prevalence of malignancy was relatively low (<6%). Those participants also constituted a high-risk population, defined by age and smoking history. In this study, participants had incidentally detected SSNs, among which the prevalence of malignancy was 83.5%, with no information presented on smoking history. Presumably, the study population was more similar to that in which the Lee model was developed, although surprisingly, performance was fairly comparable between the two models. → Thank you for your suggestion. First, our study was not based on a screening population. We believe that this is the main reason of the discrepancy in the model performance between our study and the original paper of Brock model. We discussed regarding this issue in the Discussion section. Our study population underwent CT scans due to various medical causes and comprised patients visited a tertiary medical center.
Smoking history was not investigated in our research as this was missing in a number of patients in the electronic medical records. In addition, it is well known that subsolid nodules, which represent a spectrum of adenocarcinomas, are not substantially associated with smoking (references #1-3). Thus, the smoking history gains little significance in our study. The Fleischner Society guideline (2013) also explicitly stated as follows in the recommendations for the management of subsolid nodules: "a key distinction is that, in this article, individuals with a history of smoking are not consistently differentiated from ex-smokers or those who have never smoked, in part owing to concerns regarding an increasing incidence of adenocarcinomas in younger and nonsmoking individuals". It is interesting that the performance of the Lee model, which was based on a similar population, biopsy/surgical candidates, also exhibited suboptimal performance for the differentiation of invasiveaccording to their solid portion size, if they are persistent lesions. We described as such in the 4th paragraph. The conclusion of our research that the performance of the Brock model and Lee model for the differentiation of invasive lesions among SSNs was suboptimal was clearly written in the last paragraph.
2. the selection of nodules: these are all suspicious SSNs, and the vast majority are invasive adenocarcinoma's (83.5%). However, there is no other way to have a good reference standard whether a SSN is invasive or preinvasive than resecting it, so I am also willing to accept this limitation. It is already clearly mentioned by the authors in the discussion. → As you stated, the intent of our study for the application of the prediction models to the incidentally detected surgical candidates was clearly mentioned in the main body. This study population issue was described repeatedly in the Discussion section to make sure that our population was different from that of the original paper of Brock model. We also described the prevalence of invasive lesions and preinvasive lesions in the abstract, main body and tables, which affects the interpretation of the performance measures.
